![consumerism](jpg/healthcare_consumer-e1478497357270-150x150.jpg)
M&A
-
Devices & Diagnostics, Health Tech
Abbott-Bigfoot Deal Proves That Diabetes Is a Hot Area for Digital Health Investment
This week, Abbott announced its plans to acquire Bigfoot Biomedical — a startup selling a “smart” insulin pen cap, which collects data from a user’s CGM to help them calculate the right dose. Most analysts were unsurprised to hear of the acquisition given that the two companies have been collaborating for more than six years, but they said the deal reinforces the steady pace of digital innovation in the diabetes care space.
-
What Impact Will California’s New “Transaction Review” Law Have?
California passed a law last year aimed at controlling rising healthcare costs that gave the state the ability to scrutinize healthcare deals of a certain size involving California companies. What impact can it have?
-
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
-
Devices & Diagnostics, Health Tech
Medtech Funding Expected to Pick Up In 2023 After Q1’s Low Point
Medtech funding reached its low point in the first quarter but will slowly pick back up over the rest of 2023, according to a new Pitchbook report. It noted that this year’s medtech funding total will not come close to the $19.7 billion the sector raised in 2021, and it might even come in below last year’s funding total of $13.5 billion.
-
Healthcare M&A Activity Reaches 3-Year Low, But It Might Pick Up in the Back Half of ‘23
M&A activity in the healthcare sector continued to decline in the second quarter of 2023, with the number of deals reaching its lowest point in three years. However, a new report predicted that M&A activity could increase in the second half of this year due to healthcare companies’ continually shrinking valuations and their divestitures of non-core assets.
-
How California’s New Legislation Could Affect Healthcare M&A Activity
Healthcare dealmakers must prepare for a new law and a recently-introduced bill in the California Senate, both of which aim to increase oversight in the healthcare M&A space. This is a legislative trend other states are beginning to participate in too — such as New York, Massachusetts and Connecticut.
-
Digital Health Funding Steadied in Q1 After a Year of Decline
Global funding for digital health companies finally stabilized in Q1 of this year. The sector raised $3.4 billion — this marks the first time the digital health world didn’t experience a quarter-over-quarter funding decline since Q4 of 2021. By holding steady, digital health startups defied the dwindling fundraising totals seen across the broader venture capital landscape, where funding dropped by 13% quarter-over-quarter.
-
Kaiser Permanente to Acquire Geisinger, Along with 5-6 More Health Systems in the Near Future
Kaiser Permanente announced that it expects to acquire Pennsylvania-based Geisinger Health. Kaiser’s move is part of a larger plan — Geisinger will be the first health system to join Risant Health, a new company Kaiser launched to operate nonprofit health systems under value-based care models. Kaiser said it expects to invest $5 billion in Risant and fold five or six health systems into the company over the next five years.
-
Hospital M&A Activity Remained Strong in Q1 With 15 Deals Announced
Hospital M&A activity remained strong during the first quarter of 2023, according to a new report from Kaufman Hall. Hospitals and health systems announced 15 M&A transactions in the first quarter of 2023, which almost matches the 17 transactions announced in the fourth quarter of 2022.
-
6 Takeaways From the 41st J.P. Morgan Healthcare Conference
The 41st annual J.P. Morgan Healthcare Conference concluded last week. After the pandemic prompted it to go virtual, it was back in person, smaller in size and more effective. Here are my takeaways.
-
Discover the Next-Gen Platform for Integrated Collaborative Care
Beyond EHRs and digital front doors, reducing the gaps in patient care journeys.
-
M&A Monday: AstraZeneca Leads Way as 3 Pharmas Splash Out $3.5B in Deals
AstraZeneca has committed $1.3 billion to acquire CinCor Pharma, a clinical-stage biotech whose lead drug candidate has the potential to treat hypertension in a new way. In other M&A news, Ipsen and Chiesi Farmaceutici each announced acquisitions of rare disease biotechs. All three deals come with contingent value rights.
-
Does the Rumored Amwell/Talkspace Deal Make Sense? Experts Weigh In
Some industry experts seem skeptical of the rumored deal between Amwell and Talkspace, while others disagree. The rumored purchasing price is $200 million at about $1.50 per share.
-
As M&A costs rise, new Accenture report offers alternative strategies
Rising deal premiums and shrinking profit margins are threatening the sustainability of the traditional approach to mergers and acqusitions, according to a report by Accenture. The firm expects growth-minded companies will turn to other pathways.
-
Pfizer buys its way into migraine with $11.6B Biohaven Pharma acquisition
Pfizer is turning to M&A to get its next blockbuster, buying Biohaven six months after the two companies began a commercialization pact centered on the oral migraine drug Nurtec. The acquisition will lead to the spinout of Biohaven’s other assets into a new, publicly traded company capitalized with $275 million.
-
What will digital health M&A look like in 2022?
After a busy year for digital health, four experts shared their predictions on which sectors will see the most M&A, and which companies are likely to get together in the future.
-
Oracle to buy Cerner for $28.3B
The companies struck an all-cash deal on Monday for $95-per share. Oracle plans to add a voice interface to Cerner’s electronic health record system.